Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells $509,200.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $101.84, for a total value of $509,200.00. Following the completion of the sale, the chief executive officer directly owned 2,267,500 shares in the company, valued at approximately $230,922,200. The trade was a 0.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

iRadimed Stock Performance

iRadimed stock opened at $100.86 on Friday. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $104.93. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of 61.13 and a beta of 1.09. The stock has a fifty day moving average of $96.15 and a two-hundred day moving average of $79.70.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The business had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, analysts forecast that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Announces Dividend

The company also recently disclosed a special dividend, which was paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th were given a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s payout ratio is currently 41.21%.

Hedge Funds Weigh In On iRadimed

A number of large investors have recently modified their holdings of IRMD. Royal Bank of Canada lifted its stake in shares of iRadimed by 14.7% in the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock valued at $1,354,000 after purchasing an additional 3,307 shares in the last quarter. AQR Capital Management LLC raised its holdings in iRadimed by 7.5% in the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock valued at $831,000 after buying an additional 1,108 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after buying an additional 234 shares in the last quarter. Jones Financial Companies Lllp grew its stake in iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after buying an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in iRadimed by 1.1% during the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after buying an additional 1,821 shares during the period. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IRMD. Roth Mkm set a $90.00 price target on iRadimed in a report on Friday, October 31st. Wall Street Zen downgraded iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Lake Street Capital reissued a “buy” rating and issued a $100.00 price target on shares of iRadimed in a research note on Monday, November 3rd. Finally, Zacks Research upgraded iRadimed to a “hold” rating in a report on Tuesday, November 4th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $95.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.